Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 4:40 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 5,073,003 9.990% | 658,093 (+14.91%) | View |
| 2024-11-14 4:05 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | K2 HealthVentures Equity Trust LLC | 5,324,144 9.985% | 736,110 (+16.04%) | View |
| 2024-11-14 3:05 pm Sale | 13G | TScan Therapeutics Inc. TCRX | Cormorant Asset Management LP | 0 0.000% | -2,500,000 (Position Closed) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | TScan Therapeutics Inc. TCRX | BlackRock Inc. BLK | 4,633,276 9.500% | 0 (Unchanged) | View |
| 2024-10-21 4:11 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | BlackRock Inc. BLK | 4,633,276 9.500% | 4,633,276 (New Position) | View |
| 2024-04-29 4:02 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | Cormorant Asset Management LP | 2,500,000 5.150% | 2,500,000 (New Position) | View |
| 2024-04-23 4:25 pm Purchase | 13D | TScan Therapeutics Inc. TCRX | BAKER BROS. ADVISORS LP | 2,828,938 6.100% | 35,000 (+1.25%) | View |
| 2024-02-14 4:45 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | K2 HealthVentures Equity Trust LLC | 4,588,034 9.985% | 2,488,225 (+118.50%) | View |
| 2024-02-09 4:08 pm Unchanged | 13G | TScan Therapeutics Inc. TCRX | GV 2017 L.P. | 1,077,080 2.500% | 0 (Unchanged) | View |
| 2024-02-08 06:02 am Purchase | 13G | TScan Therapeutics Inc. TCRX | Pitango HealthTech Fund I L.P. | 2,079,985 4.300% | 1,000,000 (+92.59%) | View |
| 2024-02-07 07:45 am Sale | 13G | TScan Therapeutics Inc. TCRX | ADAGE CAPITAL PARTNERS GP L.L.C. | 3,900,000 8.960% | -100,000 (-2.50%) | View |
| 2023-06-12 4:30 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,000,000 9.350% | 4,000,000 (New Position) | View |
| 2023-06-08 1:25 pm Sale | 13G | TScan Therapeutics Inc. TCRX | BlackRock Inc. BLK | 1,267,188 3.000% | -246,758 (-16.30%) | View |
| 2023-06-05 4:45 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | BIOTECHNOLOGY VALUE FUND L P | 4,414,910 9.990% | 4,414,910 (New Position) | View |
| 2023-06-05 4:09 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | EcoR1 Capital LLC | 5,000,000 11.700% | 5,000,000 (New Position) | View |
| 2023-06-02 4:56 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | Lynx1 Capital Management LP | 5,224,600 12.200% | 5,224,600 (New Position) | View |
| 2023-06-02 4:06 pm Purchase | 13D | TScan Therapeutics Inc. TCRX | BAKER BROS. ADVISORS LP | 2,793,938 6.500% | 9,146 (+0.33%) | View |
| 2023-02-14 4:11 pm Sale | 13G | TScan Therapeutics Inc. TCRX | HILLHOUSE INVESTMENT MANAGEMENT LTD. | 0 0.000% | -1,282,976 (Position Closed) | View |
| 2023-02-03 4:27 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | BlackRock Inc. BLK | 1,513,946 8.000% | 15,408 (+1.03%) | View |
| 2022-09-30 5:21 pm Purchase | 13G | TScan Therapeutics Inc. TCRX | K2 HealthVentures Equity Trust LLC | 2,099,809 9.985% | 2,099,809 (New Position) | View |